CD19 and Burkitt lymphoma: CD19-targeting 161519 TriKE, developed by Felices et al.20, has demonstrated the potential to drive a potent activating and proliferative signal to NK cells, inducing killing of a CD19-expressing Burkitt’s lymphoma cell line and primary chronic lymphocytic leukemia (CLL) targets.